Suggested remit: To appraise the clinical and cost effectiveness of tafasitamab plus lenalidomide and rituximab within its marketing authorisation for relapsed or refractory follicular lympho-ma after 1 or more systemic treatments.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6413
Provisional Schedule
- Committee meeting: 1:
- 05 May 2026
- Expected publication:
- 15 July 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 September 2025 | Invitation to participate |
| 18 July 2025 - 15 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6413 |
| 18 July 2025 | In progress. Scoping commencing |
| 21 December 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 14 December 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual